Since the GLP-1 RAs liraglutide and semaglutide have been approved for use in obesity, we analyzed use of GLP-1 RA and SGLT2-i by BMI status (not shown in table). Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.